ENOV - Enovis Corporation
Dallas, TX, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its third quarter 2026 financial results on Thursday, November 5th, 2026 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning.
electroCore (NASDAQ: ECOR - Get Free Report) and Enovis (NYSE: ENOV - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, profitability and risk. Analyst Ratings This is a breakdown of current recommendations
Nexalin Technology (NASDAQ: NXL - Get Free Report) and Enovis (NYSE: ENOV - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation. Institutional and Insider Ownership 0.7% of Nexalin Technology
Company expands its support from the American Joint Replacement Registry to include the Shoulder & Elbow Registry ROSEMONT, Ill., Sept. 22, 2026 /PRNewswire/ -- The American Academy of Orthopaedic Surgeons (AAOS) announced that Enovis ™ has expanded its support of the AAOS Registry Program, becoming the first industry partner to sponsor multiple AAOS registries.
Enovis Corporation (NYSE: ENOV - Get Free Report)'s share price reached a new 52-week low during mid-day trading on Wednesday. The stock traded as low as $17.30 and last traded at $17.9220, with a volume of 2658431 shares changing hands. The stock had previously closed at $18.22. Analysts Set New Price Targets ENOV has been
Engert's $150,000 purchase represents a 14% increase to his direct holdings, signaling confidence despite stock's -37% one-year decline.
Enovis (ENOV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Enovis (ENOV) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
ENOV is set to acquire eCential Robotics to expand into orthopedic surgical robotics, though the deal is expected to pressure 2027 margins.
Enovis Corporation (ENOV) M&A Call Transcript
Enovis NYSE: ENOV said it has entered a binding offer to acquire eCential Robotics, a developer of surgical robotics technology, in a move the orthopedic company said will expand its enabling-technology capabilities and accelerate its pathway into robotic surgery.
eCential Robotics platform to join Enovis' enabling technology portfolio. GRENOBLE, France and FRANKLIN, Tenn.
Dallas, TX, Sept. 01, 2026 (GLOBE NEWSWIRE) -- – Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology company, announced today that it has entered into a binding offer to acquire eCential Robotics, a leading developer of enabling technologies and surgical robotics. The acquisition expands the ASTRA™ enabling technology platform with robotic automation capabilities, creating a more comprehensive ecosystem designed to improve surgical precision, streamline workflows, and enhance patient outcomes.
Dallas, TX, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that it will participate in the 2026 Wells Fargo HealthCare conference on Tuesday, September 8, 2026 at the Encore Boston Harbor.
Enovis Corporation is rated a buy, trading at a 7x EBITDA multiple versus a sector median of 14.7x, with significant upside if Arvis succeeds. Arvis, a zero-footprint, wearable augmented reality device for orthopedic surgery, targets the fast-growing ambulatory surgery center market and recently achieved full commercialization. ENOV's fundamentals are weak—slim margins, high leverage, and thin free cash flow—but these are already priced in, while Arvis's growth potential is not.
Enovis is gaining share in joint reconstruction, leveraging new products and capitalizing on competitor disruptions. Q2 results beat expectations, with 4% organic revenue growth and improved margins, but guidance now anticipates a more Q4-weighted second half. ENOV is making progress on cash flow conversion and deleveraging, and should reach sub-2.0x net debt/EBITDA within three years.
California State Teachers Retirement System raised its stake in shares of Enovis Corporation (NYSE: ENOV) by 38.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 76,966 shares of the company's stock after acquiring an additional 21,571 shares during the quarter. California
Odyssey Health (OTCMKTS:ODYY - Get Free Report) and Enovis (NYSE: ENOV - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk. Institutional and Insider Ownership 98.5% of Enovis shares are
Enovis (NYSE: ENOV - Get Free Report) and ADB International Group (OTCMKTS:EQUR - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk. Earnings and Valuation This table compares Enovis and
Enovis NYSE: ENOV reported second-quarter 2026 sales of $583 million, up 3% on a reported basis and 5% organically, as growth in its Reconstruction business offset a slower but still expanding Performance & Recovery segment. Management said the company's results reflected improved commercial execution, new-product adoption and operational productivity, while also noting pressure from Middle East-related disruptions and higher inflation.